Tag: equity
-
Gene Editing Licensed for Inherited Disease Treatments
26 October 2015. A Boston biotechnology company is licensing gene-editing technologies from a nearby start-up to design treatments for cystic fibrosis and inherited blood disorders, including sickle cell disease. Vertex Pharmaceuticals, in Boston, received rights to techniques known as CRISPR-Cas9 in a deal that could bring CRISPR Therapeutics, founded in April 2014, as much as…
-
Immunotherapy Start-Up Gains $102M in Venture Funds
20 October 2015. A new enterprise founded by researchers in the U.S. and Europe that aims to provide personalized cancer therapies harnessing the immune system raised $102 million in its first round of venture financing. The company Gritstone Oncology — in San Francisco and Cambridge, Massachusetts — says it plans to focus initially on developing…
-
Harvard Spin-Off Commercializing Sepsis Treatment
9 October 2015. A new enterprise spun-off from Harvard University is developing a device for treating sepsis, a life-threatening infection often contracted in hospitals. The company, Opsonix Inc. in Boston, also raised $8 million in its first round of venture funding. Opsonix is licensing a technology for treating sepsis developed in Harvard’s Wyss Institute for…
-
MD Anderson, Biotech Form Antibody Discovery Company
7 October 2015. MD Anderson Cancer Center in Houston is partnering with the biotechnology company Theraclone Sciences to form a new enterprise devoted to discovering antibodies for cancer therapies harnessing the immune system. The company named OncoResponse, also based in Houston, attracted $9.5 million in its first venture funding round. OncoResponse plans to adapt Theraclone’s…
-
RNA Therapy Biotech Earns $44 Million in IPO
1 October 2015. A biotechnology company developing therapies based on RNA, genetic material that sends signals to cells, raised $43.75 million in its initial public stock offering. Mirna Therapeutics Inc. in Austin, Texas issued 6.25 million shares today at $7.00, and trades on the Nasdaq exchange under the symbol MIRN. Its shares closed today at…
-
Diabetes Biotech Acquires GSK Spin-Off
24 September 2015. Intarcia Therapeutics, a developer of long-acting treatments for diabetes, is purchasing Phoundry Pharmaceuticals, a discoverer of engineered peptides for metabolic and other disorders. Phoundry — a spin-off company from GlaxoSmithKline in Research Triangle Park, North Carolina — is being acquired by Intarcia for an undisclosed amount of cash and stock. Intarcia, based…
-
Genome Editing Biotech Gains $70M in Venture Funds
1 September 2015. Intellia Therapeutics, a developer of therapies that edit human genomes to fix inherited disorders, raised $70 million in its second round of venture financing. OrbiMed HealthCare Fund Management led the funding round for the Cambridge, Massachusetts enterprise, with new and current investors taking part. Intellia Therapeutics, founded in November 2014, is a…
-
Synthetic Biology Company Raises $200 Million in IPO
21 August 2015. Intrexon Corp., a company developing genomic solutions with synthetic biology, raised some $200 million in its initial public stock offering. The Germantown, Maryland enterprise issued 4,878,049 shares of common stock priced at $41.00, and traded on the New York Stock Exchange under the symbol XON. The company’s shares closed today at $45.46,…
-
Blood Disease Biotech Gains $120 Million in IPO
12 August 2015. Global Blood Therapeutics, a biotechnology company developing treatments for blood-related disorders, is raising $120 million in its initial public stock offering. The company, in South San Francisco, California and trading on the Nasdaq exchange under the symbol GBT, issued 6 million shares priced at $20.00. Shares closed today trading at $43.50, more…
-
Intrexon Acquires Oxitec, Partners on Genetic Disorder
10 August 2015. Intrexon Corp., a biotechnology company specializing in synthetic biology, is acquiring Oxitec Ltd., a designer of genetically modified insects to control the spread of disease-bearing and agricultural pests for $160 million. Intrexon is also partnering with Synthetic Biologics Inc. to develop therapies for phenylketonuria, a genetic metabolic disorder. Intrexon, in Gaithersburg, Maryland…